Ocular Therapeutix, Inc
Ocular Therapeutix, Inc. is a U.S.-based biopharmaceutical company focused on ophthalmology, with products and product candidates built around its ELUTYX bioresorbable hydrogel delivery technology. Its portfolio includes the approved ocular therapy DEXTENZA and investigational programs for retinal disease and glaucoma, including AXPAXLI and OTX-TIC.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDEXTENZA is the company’s approved ocular insert sold in the U.S. for post-surgical inflammation, pain, and allergic conjunctivitis.
AXPAXLI is an investigational intravitreal hydrogel candidate being developed for wet AMD and diabetic retinal disease.
OTX-TIC is an investigational intracameral hydrogel candidate for open-angle glaucoma and ocular hypertension.
ELUTYX is the proprietary bioresorbable hydrogel platform used to deliver therapeutic agents to the eye.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products99,8 %
- Collaboration Revenue0,2 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells DEXTENZA primarily through a small number of specialty distributors in the United States, which then resell to ambulatory surgical centers, hospital outpatient departments, and physicians’ offices. It also sells directly to a smaller set of ASCs and physician offices, and future products are expected to follow similar ophthalmology-focused channels if approved.
Buy DEXTENZA in bulk and distribute it to ophthalmic care sites; they are the main commercial channel.
Use DEXTENZA in connection with ophthalmic surgery, especially cataract-related procedures.
Purchase DEXTENZA for outpatient eye-surgery workflows and post-operative care.
Use office-administered DEXTENZA for approved indications and may adopt future office-based therapies.
Potential future prescribers of AXPAXLI and OTX-TIC if those candidates are approved.
Strategia
The company’s strategy centers on building an ophthalmology franchise around its ELUTYX hydrogel platform, using DEXTENZA as the commercial base and advancing AXPAXLI and OTX-TIC through clinical development. It also uses selective licensing to extend reach in certain Asian markets while retaining broader global rights for its core assets.
AXPAXLI is the main pipeline asset and could expand the company beyond DEXTENZA.
Commercial execution on the approved product supports the base business and physician familiarity with the platform.
A common delivery platform can create a pipeline of differentiated products with local release properties.
Licensing can extend reach without building a full international commercial infrastructure.
Maantiede
Ocular Therapeutix is headquartered in the United States and derives its commercial product revenue from U.S. sales of DEXTENZA. The company also has out-licensing rights in specified Asian markets through AffaMed, while retaining rights in other global markets for DEXTENZA and OTX-TIC.
Riskit
The business depends on a narrow commercial base, a small number of specialty distributors, and successful adoption by ophthalmology providers, so customer concentration and reimbursement dynamics are important risks. Clinical, regulatory, and intellectual-property outcomes for AXPAXLI and OTX-TIC are also central because the company’s future growth depends on advancing these candidates through development and approval.
- Customer concentration in the DEXTENZA channelVaikutus: KorkeaTodennäköisyys: Kohtalainen
A small number of specialty distributors account for most revenue, so losing one could materially reduce sales.
Kohdistuu: Three specialty distributors accounted for a large share of total revenue in recent years.
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
AXPAXLI and OTX-TIC are still investigational, and trial setbacks would delay or eliminate future product revenue.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Ophthalmic drugs require FDA and other regulatory approvals before commercialization.
Kohdistuu - Intellectual property erosionVaikutus: KorkeaTodennäköisyys: Kohtalainen
If patent protection is narrower than expected, competitors could launch similar products.
Kohdistuu: ELUTYX platform and product candidates
- Competitive and reimbursement pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Alternative therapies may be cheaper, more convenient, or better reimbursed, limiting adoption.
Kohdistuu: DEXTENZA and future retina products
Kirjanpito
Harkinnanvaraiset erätRebates, chargebacks, and channel inventory estimates reduce gross sales and require judgment each period.
Vaikutus: Affects net product revenue and current liabilities
Distributor and direct-sale arrangements require contract and performance-obligation analysis.
Vaikutus: Determines when DEXTENZA sales are recorded
AffaMed milestone and clinical support payments are recognized as performance obligations are satisfied.
Vaikutus: Can create lumpy non-product revenue
The royalty fee derivative is measured using a Monte Carlo simulation and revenue assumptions.
Vaikutus: Fair-value changes flow through other income (expense)
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
EyePoint, Inc.
EYPT · Laboratory Analytical Instruments
Outlook Therapeutics, Inc.
OTLK · Biological Products, (No Diagnostic Substances)
IRIDEX Corporation
IRIX · Electromedical & Electrotherapeutic Apparatus
IRIDEX Corp is an ophthalmic medical technology company that develops and commercializes laser-based systems and related therapies for sight-threatening eye diseases.
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
LENZ Therapeutics, Inc.
LENZ · Biological Products, (No Diagnostic Substances)
LENZ Therapeutics is a U.S.-based pre-commercial biopharmaceutical company focused on developing and commercializing VIZZ, an aceclidine-based eye drop for presbyopia.
GLAUKOS Corp
GKOS · Surgical & Medical Instruments & Apparatus
Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments.
Päivitetty: 24.9.2026